Efficacy and safety of mirikizumab as maintenance therapy in patients with moderately to severely active ulcerative colitis: Results from the Phase 3 LUCENT-2 study

J. Begun; M.C. Dubinsky; P.M. Irving; X. Li; S. Howaldt; J. Pokrotnieks; K. Krueger; J. Laskowski; T. Lissoos; J. Milata; N. Morris; V. Arora; C. Milch; B.E. Sands

doi:10.1111/jgh.15953

Efficacy and safety of mirikizumab as maintenance therapy in patients with moderately to severely active ulcerative colitis: Results from the Phase 3 LUCENT-2 study

J. Begun, M.C. Dubinsky, P.M. Irving, X. Li, S. Howaldt, J. Pokrotnieks, K. Krueger, J. Laskowski, T. Lissoos, J. Milata, N. Morris, V. Arora, C. Milch, B.E. Sands

Rīga Stradiņš University

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Article number	115
Pages (from-to)	133
Journal	Journal of Gastroenterology and Hepatology
Volume	37
Issue number	Suppl.1
DOIs	https://doi.org/10.1111/jgh.15953
Publication status	Published - Sept 2022
Event	Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW): Bidirectional Learning – a foundation for excellence & innovation - Sidney, Australia Duration: 9 Sept 2022 → 11 Sept 2022 https://agw.gesa.org.au/ https://www.emedevents.com/medical-hybrid-events-2022/gastroenterological-society-of-australia-gesa-australian-gastroenterology-week-agw-2022

Field of Science*

3.2 Clinical medicine

Publication Type*

3.3. Publications in conference proceedings indexed in Web of Science and/or Scopus database

Access to Document

10.1111/jgh.15953

Cite this

Begun, J., Dubinsky, M. C., Irving, P. M., Li, X., Howaldt, S., Pokrotnieks, J., Krueger, K., Laskowski, J., Lissoos, T., Milata, J., Morris, N., Arora, V., Milch, C., & Sands, B. E. (2022). Efficacy and safety of mirikizumab as maintenance therapy in patients with moderately to severely active ulcerative colitis: Results from the Phase 3 LUCENT-2 study. Journal of Gastroenterology and Hepatology, 37(Suppl.1), 133. Article 115. https://doi.org/10.1111/jgh.15953

@article{c5432517f8c44979b4b99914141d46cd,

title = "Efficacy and safety of mirikizumab as maintenance therapy in patients with moderately to severely active ulcerative colitis: Results from the Phase 3 LUCENT-2 study",

author = "J. Begun and M.C. Dubinsky and P.M. Irving and X. Li and S. Howaldt and J. Pokrotnieks and K. Krueger and J. Laskowski and T. Lissoos and J. Milata and N. Morris and V. Arora and C. Milch and B.E. Sands",

year = "2022",

month = sep,

doi = "10.1111/jgh.15953",

language = "English",

volume = "37",

pages = "133",

journal = "Journal of Gastroenterology and Hepatology",

issn = "0815-9319",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "Suppl.1",

note = "Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) : Bidirectional Learning – a foundation for excellence & innovation, GESA AGW 2022 ; Conference date: 09-09-2022 Through 11-09-2022",

url = "https://agw.gesa.org.au/, https://www.emedevents.com/medical-hybrid-events-2022/gastroenterological-society-of-australia-gesa-australian-gastroenterology-week-agw-2022",

}

Begun, J, Dubinsky, MC, Irving, PM, Li, X, Howaldt, S, Pokrotnieks, J, Krueger, K, Laskowski, J, Lissoos, T, Milata, J, Morris, N, Arora, V, Milch, C & Sands, BE 2022, 'Efficacy and safety of mirikizumab as maintenance therapy in patients with moderately to severely active ulcerative colitis: Results from the Phase 3 LUCENT-2 study', Journal of Gastroenterology and Hepatology, vol. 37, no. Suppl.1, 115, pp. 133. https://doi.org/10.1111/jgh.15953

Efficacy and safety of mirikizumab as maintenance therapy in patients with moderately to severely active ulcerative colitis: Results from the Phase 3 LUCENT-2 study. / Begun, J.; Dubinsky, M.C.; Irving, P.M. et al.
In: Journal of Gastroenterology and Hepatology, Vol. 37, No. Suppl.1, 115, 09.2022, p. 133.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - Efficacy and safety of mirikizumab as maintenance therapy in patients with moderately to severely active ulcerative colitis

T2 - Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW)

AU - Begun, J.

AU - Dubinsky, M.C.

AU - Irving, P.M.

AU - Li, X.

AU - Howaldt, S.

AU - Pokrotnieks, J.

AU - Krueger, K.

AU - Laskowski, J.

AU - Lissoos, T.

AU - Milata, J.

AU - Morris, N.

AU - Arora, V.

AU - Milch, C.

AU - Sands, B.E.

PY - 2022/9

Y1 - 2022/9

UR - https://www-webofscience-com.db.rsu.lv/wos/alldb/full-record/WOS:000852585700205

UR - https://onlinelibrary.wiley.com/doi/10.1111/jgh.15953

U2 - 10.1111/jgh.15953

DO - 10.1111/jgh.15953

M3 - Meeting Abstract

SN - 0815-9319

VL - 37

SP - 133

JO - Journal of Gastroenterology and Hepatology

JF - Journal of Gastroenterology and Hepatology

IS - Suppl.1

M1 - 115

Y2 - 9 September 2022 through 11 September 2022

ER -

Efficacy and safety of mirikizumab as maintenance therapy in patients with moderately to severely active ulcerative colitis: Results from the Phase 3 LUCENT-2 study

Field of Science*

Publication Type*

Access to Document

Other files and links

Efficacy and Safety of Mirikizumab As Maintenance Therapy in Patients with Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 Lucent-2 Study

Cite this